Evidence map›Paper›PMID 42740933›Full record

ArticleInternational journal of cardiology. Heart & vasculature2026

Annual assessment of ECG intervals in patients with myotonic dystrophy type 1 using a mobile 6‑lead ECG device: TeleCheck-DM1.

David S H Bovenkerk, Leandre A La Fontaine, Astrid N L Hermans, Sander M J van Kuijk, Isis B T Joosten, Catharina G Faber, Theo A R Lankveld, Dennis den Uijl, Kevin Vernooy, Jeroen M Hendriks and 2 more

Abstract read
In one paragraph

Article in International journal of cardiology. Heart & vasculature, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

David S H BovenkerkDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Leandre A La FontaineDepartment of Neurology, Maastricht University Medical Centre (MUMC+), School for Mental Health and Neuroscience, Maastricht, The Netherlands.
Astrid N L HermansDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Sander M J van KuijkDepartment of Clinical Epidemiology and Medical Technology Assessment, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Isis B T JoostenDepartment of Neurology, Maastricht University Medical Centre (MUMC+), School for Mental Health and Neuroscience, Maastricht, The Netherlands.
Catharina G FaberDepartment of Neurology, Maastricht University Medical Centre (MUMC+), School for Mental Health and Neuroscience, Maastricht, The Netherlands.
Theo A R LankveldDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Dennis den UijlDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Kevin VernooyDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Jeroen M HendriksDepartment of Nursing, Maastricht University Medical Centre (MUMC+), Maastricht, The Netherlands.
Dominik LinzDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Ben J M HermansDepartment of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background and aims: Cardiac involvement occurs in approximately 80% of patients with myotonic dystrophy type 1 (DM1), and annual follow-up with a routine 12‑lead ECG (rECG) is recommended. We assessed a mobile 6‑lead ECG device (mECG) as a triage tool to identify DM1 patients with suspected prolonged ECG intervals, validating the feasibility and accuracy of mECG-derived PQ and QRS intervals against rECG. Methods: This supervised in-clinic proof-of-concept study included 50 patients with DM1 and 50 cardiology patients from the cardiology outpatient clinic. All underwent rECG and mECG during a single routine visit. Agreement was assessed using correlation, intra-class correlation coefficient (ICC), and Bland-Altman analyses. Results: Median [IQR] age was 56 [40-66] years; 45% were women. mECG-derived PQ and QRS intervals correlated moderately to strongly with rECG (Pearson's Conclusion: mECG is feasible in patients with DM1 and provides reliable assessment of PQ intervals. Integrated into annual cardiac follow-up, it could serve as a triage tool, potentially reducing outpatient visits by 37% for DM1. This may become increasingly valuable as novel DM1 therapies expand the population requiring regular cardiac surveillance. QRS triage is unsuitable in its current form.

Indexed as

ECGeHealthMyotonic dystrophy type 1Telemonitoring

Identifiers

PMID42740933
PMCPMC13572175

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.